miRNA Profiling: How to Bypass the Current Difficulties in the Diagnosis and Treatment of Sarcomas

Sarcomas are divided into a group with specific alterations and a second presenting a complex karyotype, sometimes difficult to diagnose or with few therapeutic options available. We assessed if miRNA profiling by TaqMan low density arrays could predict the response of undifferentiated rhabdomyosarcoma (RMS) and osteosarcoma to treatment. We showed that miRNA signatures in response to a therapeutic agent (chemotherapy or the mTOR inhibitor RAD-001) were cell and drug specific on cell lines and a rat osteosarcoma model. This miRNA signature was related to cell or tumour sensitivity to this treatment and might be not due to chromosomal aberrations, as revealed by a CGH array analysis of rat tumours. Strikingly, miRNA profiling gave promising results for patient rhabdomyosarcoma, discriminating all types of RMS: (Pax+) or undifferentiated alveolar RMS as well as embryonal RMS. As highlighted by these results, miRNA profiling emerges as a potent molecular diagnostic tool for complex karyotype sarcomas

The Lantern Vol. 57, No. 1, Fall 1990

• Candlelight Ecstasy Tabitha • Waffle Maker • Thoughts From the Street Corner • The Grip • Eugenio\u27s Room • Amnesiac • Life at the Edge • College Love • Dry Ice and Red Roses • Forever a Monument • Melanie • Respectable Man • Conversation With Craig • Cheddar Cheese Trees • The Jazz Butcher vs. The Oreos • Sally\u27s Home From Vacation • So She Saidhttps://digitalcommons.ursinus.edu/lantern/1137/thumbnail.jp

Towards drop your thesis 2018: 4.7 seconds of microgravity conditions to enable future CubeSat landings on asteroids

An increasing number of interplanetary missions are aiming at visiting asteroids and other small bodies, since these may provide clues to understand the formation and evolution of our Solar System. CubeSats allow a low-cost solution to land on these objects, as opposed to risking a much more expensive mothership. The weak gravitational field on these small bodies may also enable the possibility of simply dropping a CubeSat from afar (i.e. ballistic landing). However, ballistic landing of an unpowered spacecraft may be feasible solely within certain asteroid locations, and only if sufficient energy can be dissipated at touchdown. If such conditions are not met, the spacecraft will rebound off the surface. It is likely that the necessary energy dissipation may already occur naturally due to energy loss expected through the deformation of the regolith during touchdown. Indeed, previous low-velocity impact experiments in microgravity seem to indicate that this is exactly the case. However, data from past asteroid touchdowns, Hayabusa and Philae, indicate the contrary. This paper describes the development of an experiment which aims to bridge the aforementioned disagreement between mission data and microgravity experiment; to understand the behaviour of CubeSat landing on asteroids. The experiment will also test a novel damping system made by origami paper that should increase the dissipated energy at touchdown. The experiment will take place at the ZARM Drop Tower in Bremen in November 2018. With the constraint of 5 drops, the experiment will measure the coefficient of restitution during an available time window of 4.74 seconds of microgravity conditions. A 1UCubeSat mock-up will be used to represent a future asteroid lander. In order to mimic the landing of actual missions, the mock-up will have a mass of about 4 kg and it will be given a velocity of 15 cm/s with minimal rotation. This will be achieved by an automated spring-based release mechanism. An asteroid simulant, ESA03-A KM Bentonite Granules will be used to replicate an asteroid mechanical properties at the surface. This paper reviews the final design and the engineering challenges of the experiment

Quality of Life and Utility in Patients with Metastatic Soft Tissue and Bone Sarcoma: The Sarcoma Treatment and Burden of Illness in North America and Europe (SABINE) Study

The aim of the study was to assess health-related quality of life (HRQoL) among metastatic soft tissue (mSTS) or bone sarcoma (mBS) patients who had attained a favourable response to chemotherapy. We employed the EORTC QLQ-C30, the 3-item Cancer-Related Symptoms Questionnaire, and the EQ-5D instrument. HRQoL was evaluated overall and by health state in 120 mSTS/mBS patients enrolled in the SABINE study across nine countries in Europe and North America. Utility was estimated from responses to the EQ-5D instrument using UK population-based weights. The mean EQ-5D utility score was 0.69 for the pooled patient sample with little variation across health states. However, patients with progressive disease reported a clinically significant lower utility (0.56). Among disease symptoms, pain and respiratory symptoms are common. This study showed that mSTS/mBS is associated with reduced HRQoL and utility among patients with metastatic disease

The Lantern Vol. 59, No. 1, December 1991

• And I Believed Them • Silly Rabbit • The Sky Seemed Endless • Here Boy • Bill the Person • The Crash • Gifts of Edward Charles and Me • Inspiration Incorporated • The Last Morning • Something\u27s Fishy • The Comforter • The Castle Builders • Saturday Skeleton Crew • The Convent\u27s Light • In My Veins • My Own Little Hell • Idling • You Know Who You Are • Pooh • The Pondhttps://digitalcommons.ursinus.edu/lantern/1140/thumbnail.jp

The Lantern Vol. 56, No. 2, Spring 1990

• Brasil • Plastic Flowers • Be a Pepper • Grunge • Handling the Responsibility • Returning to the Forest • How Nice • Nooze • Emma • Restoration • Chestnuts • Frozen Moments • Once Upon A • Clipped Wings • Gerard Manley Hopkins • Roaches • In Grand Central • The Steelville Shark • Panama 1989 • Betrayal • Violations • Detourhttps://digitalcommons.ursinus.edu/lantern/1136/thumbnail.jp

The Lantern Vol. 58, No. 2, Summer 1991

• We All Fall Up • Clerical Nightmares • The Brass Bed • Mon Amour • The Lady of J. Alfred Prufrock • Forbidden Places • Edge of the Dance • Crystal World • Saturday, July 12, 1978, 4:59 pm • Of You I Think • Just Another Statistic • A $16 Word in a$4.99 Trashcan • Souvenir • The Jester • Against a Rock • I Wish I Were a Fish • Too Small, Too Weak • Somewheres in N.Y.C. • Stuck Up • Patterns • I Should Tell You Now • Me, Tommy, and Miss May • Two Hands • All-Natural, Organically Grown Macadamia Butter • Irony of a Suburban Deathhttps://digitalcommons.ursinus.edu/lantern/1138/thumbnail.jp

The Grizzly, March 26, 1991

First Dance Marathon for Leukemia a Success • U.S.G.A. Proposes S.A.C. Reorganization • Student Debate on Use of Force Held • College Fax for Official College Use • Residential Village Centralized • New Materials to Recycle • Financial Aid Update • The Soviets: An Inside Portrait • Communication Arts Career Night • Lange Promoted to Assistant Dean of Continuing Education • 1990 Fall Dean\u27s List • Symposium at Berman • Men\u27s Track Runs Well Despite Conditions • Women\u27s Track Makes a Splash at Greyhound Invitational • Women Win ECAC Title • Men\u27s Lacrosse Upsets Penn State Del. Co. • Women\u27s Lacrosse Hopes for Third NCAA Title • Golf Opens With a Win • Derstine First Swimming All-American • Softball Swings into Season • Men\u27s Tennis Nets Good Results • Letter: Student Apathy, Who Cares! • The New Drugstore: Nature\u27s Pharma-Sea • Don\u27t Can Your Aluminumhttps://digitalcommons.ursinus.edu/grizzlynews/1274/thumbnail.jp

Clinical Study Quality of Life and Utility in Patients with Metastatic Soft Tissue and Bone Sarcoma: The Sarcoma Treatment and Burden of Illness in North America and Europe (SABINE) Study

The aim of the study was to assess health-related quality of life (HRQoL) among metastatic soft tissue (mSTS) or bone sarcoma (mBS) patients who had attained a favourable response to chemotherapy. We employed the EORTC QLQ-C30, the 3-item CancerRelated Symptoms Questionnaire, and the EQ-5D instrument. HRQoL was evaluated overall and by health state in 120 mSTS/mBS patients enrolled in the SABINE study across nine countries in Europe and North America. Utility was estimated from responses to the EQ-5D instrument using UK population-based weights. The mean EQ-5D utility score was 0.69 for the pooled patient sample with little variation across health states. However, patients with progressive disease reported a clinically significant lower utility (0.56). Among disease symptoms, pain and respiratory symptoms are common. This study showed that mSTS/mBS is associated with reduced HRQoL and utility among patients with metastatic disease

Inhibition of Chondrosarcoma Growth by mTOR Inhibitor in an In Vivo Syngeneic Rat Model

BACKGROUND: Chondrosarcomas are the second most frequent primary malignant type of bone tumor. No effective systemic treatment has been identified in advanced or adjuvant phases for chondrosarcoma. The aim of the present study was to determine the antitumor effects of doxorubicin and everolimus, an mTOR inhibitor on chondrosarcoma progression. METHODS AND FINDINGS: Doxorubin and/or everolimus were tested in vivo as single agent or in combination in the rat orthotopic Schwarm chondrosarcoma model, in macroscopic phase, as well as with microscopic residual disease. Response to everolimus and/or doxorubicin was evaluated using chondrosarcoma volume evolution (MRI). Histological response was evaluated with % of tumor necrosis, tumor proliferation index, metabolism quantification analysis between the treated and control groups. Statistical analyses were performed using chi square, Fishers exact test. Doxorubicin single agent has no effect of tumor growth as compared to no treatment; conversely, everolimus single agent significantly inhibited tumor progression in macroscopic tumors with no synergistic additive effect with doxorubicin. Everolimus inhibited chondrosarcoma proliferation as evaluated by Ki67 expression did not induce the apoptosis of tumor cells; everolimus reduced Glut1 and 4EBP1 expression. Importantly when given in rats with microscopic residual diseases, in a pseudo neoadjuvant setting, following R1 resection of the implanted tumor, everolimus significantly delayed or prevented tumor recurrence. CONCLUSIONS: MTOR inhibitor everolimus blocks cell proliferation, Glut1 expression and HIF1a expression, and prevents in vivo chondrosarcoma tumor progression in both macroscopic and in adjuvant phase post R1 resection. Taken together, our preclinical data indicate that mTOR inhibitor may be effective as a single agent in treating chondrosarcoma patients. A clinical trial evaluating mTOr inhibitor as neo-adjuvant and adjuvant therapy in chondrosarcoma patients is being constructed